Oak Review

Oak's verdict: one flat price, no dose-creep penalty — and it just got cheaper

Oak (run by Oak Longevity Holdings Corp.) is built around a single idea most GLP-1 telehealth services don't honor: you pay one price no matter what dose you're on. For semaglutide that's $200 a month, every month, from starter dose to full titration — and that headline rate actually dropped at our latest re-check, not rose. But it's compounded-only, the pharmacy isn't named, and the fine print is unusually strict, so it isn't for everyone.

The flat-rate claim, and what Oak's own checkout says about it

Oak sells on one idea: most compounded telehealth pricing is tiered, so the milligrams go up and your monthly charge goes up with them, and Oak says it does not do that. The banner is three words — one price, all dosages — and compounded semaglutide is listed at $200 per month with compounded tirzepatide above it. Read the checkout page, though, and Oak contradicts its own banner. Its FAQ there states that the final charge depends on the dose the doctor settles on, and that every step up is roughly fifty to seventy-five dollars more. Both sentences are live on the site at the same time. We take the checkout wording as the operative one, because that is the page where the money changes hands — so treat the flat rate as a marketing position rather than a guarantee, and expect the bill to move as your dose does. Discount code OAKSAVE200 is the one offer with published mechanics: fifty dollars off the first month, or two hundred off a three-month plan.

The reason any of this matters is that GLP-1 dosing escalates over the first several months, so on a tiered plan the maintenance dose — the one where the medication actually works — is also the dearest. Oak's pitch is that your month-three bill matches your month-one bill, and against a category median of $170 the semaglutide rate is still competitive. But the housekeeping is genuinely poor for a company that sells on price: at our August re-check, six different headline figures for the same medication were live across Oak's own pages simultaneously, ranging from a stale FAQ number to the checkout rate we record here. Both compounded prices are also up sharply since spring, not down. We anchor on the checkout catalog because it is the only figure attached to a transaction; if you are comparing Oak against anyone else, price it from there and not from whichever page you happen to land on.

• Free shipping is included, not an add-on at checkout.
• Free health coaching comes standard with the medication.
• No video call is required — it's an asynchronous intake form.
• Pricing is shown before intake, so you know the number before handing over health information.

What Oak prescribes and how it reaches you

Oak offers exactly two medications: compounded semaglutide and compounded tirzepatide, both injectable. There is no oral version and no brand-name option — you will not get Wegovy, Ozempic, Zepbound, or Mounjaro here. Prescriptions are issued through NVP Medical Group, P.A. You fill out the online health form, check out, and a licensed provider reviews your information — approval can come within hours, after which Oak's partner pharmacies fill the prescription and ship it free.

The real differentiator — and its honest catch

Oak's genuine edge is the no-markup-as-you-titrate model bundled with free shipping and coaching; for a long-term GLP-1 user, predictable pricing is the whole game, and few competitors guarantee it. The standout catch is transparency: Oak still refers only to 'licensed U.S. compounding pharmacies' without naming them anywhere on the public site. For a medication you inject, not knowing which pharmacy fills it is a real disclosure gap.

What customers say

This is a genuine improvement since our earlier reviews, when Oak had essentially no external review footprint. Its claimed Trustpilot profile now shows a 4.6 out of 5 'Excellent' rating from 53 reviews, and the company has replied to 100% of its negative reviews — a small but real signal someone is minding the store. The counterweight: there's still no BBB listing and no Google business profile we could locate, so those 53 reviews are the entire independent record. Encouraging, but thin.

Who should pick Oak — and who should walk

Oak is a good fit if you want compounded semaglutide or tirzepatide at the lowest stable price you can find, you're comfortable with an injection, and you'd rather skip a live video consult. The flat rate rewards people who plan to stay on therapy long-term and climb to a maintenance dose.

Skip Oak if you specifically want brand-name medication (it offers none), if you need an oral pill instead of an injection, or if naming your pharmacy upfront is a dealbreaker. Also weigh the fine print: there is no money-back guarantee, fees are non-refundable per the Terms of Use, and disputes go to binding arbitration under Delaware law.

Trust, safety, and medical oversight

On the reassuring side: Oak carries a LegitScript certification, prescriptions run through a licensed medical group, and our check of the FDA warning-letter database turned up no actions against Oak Longevity Holdings Corp. On the cautious side, we rate verification confidence as medium: the pharmacy partners aren't publicly named, the claimed 45-state coverage list is gated behind the signup intake, and the medication is compounded rather than FDA-approved brand product. None of these are red flags alone; together they're why Oak's trust score stays capped despite the improving value story. See our scoring methodology for how we weigh these factors.

Bottom line

Oak markets itself on removing the dose-creep penalty — the thing that makes most compounded GLP-1 plans get more expensive exactly when they start working — and at $200 a month for semaglutide against a $170 category median, with free shipping and coaching included, the headline is competitive. The problem is that Oak's own checkout page tells you the penalty has not been removed: it says each step up in dose runs roughly fifty to seventy-five dollars more. That is the opposite of the banner, and it is the version written on the page where you pay. So the honest read is that Oak is priced well at the starting dose and unquantifiable at the maintenance dose, which is the one that matters over a year. Add the rest with your eyes open: compounded and injectable only, the pharmacy is not named, prices rose sharply over the summer, six different headline figures were live across its own pages when we last checked, and the no-refund, arbitration-only terms are stricter than most. Worth a look if you are starting out and price-sensitive. Not the flat-rate certainty the banner sells.

Worth pricing against Breeze Meds ($199/month) and Collective ($59/month) before you commit — both sit close to Oak on cost and formulation.